138 related articles for article (PubMed ID: 17599765)
1. Altered gene expression in mice with lupus treated with edratide, a peptide that ameliorates the disease manifestations.
Elmann A; Sharabi A; Dayan M; Zinger H; Ophir R; Mozes E
Arthritis Rheum; 2007 Jul; 56(7):2371-81. PubMed ID: 17599765
[TBL] [Abstract][Full Text] [Related]
2. Amelioration of brain pathology and behavioral dysfunction in mice with lupus following treatment with a tolerogenic peptide.
Lapter S; Marom A; Meshorer A; Elmann A; Sharabi A; Vadai E; Neufeld A; Sztainberg Y; Gil S; Getselter D; Chen A; Mozes E
Arthritis Rheum; 2009 Dec; 60(12):3744-54. PubMed ID: 19950283
[TBL] [Abstract][Full Text] [Related]
3. Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase.
Rapoport MJ; Sharabi A; Aharoni D; Bloch O; Zinger H; Dayan M; Mozes E
Clin Immunol; 2005 Dec; 117(3):262-70. PubMed ID: 16257268
[TBL] [Abstract][Full Text] [Related]
4. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression.
Sthoeger ZM; Sharabi A; Molad Y; Asher I; Zinger H; Dayan M; Mozes E
J Autoimmun; 2009 Aug; 33(1):77-82. PubMed ID: 19346102
[TBL] [Abstract][Full Text] [Related]
5. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action.
Sharabi A; Azulai H; Sthoeger ZM; Mozes E
Immunology; 2007 Jun; 121(2):248-57. PubMed ID: 17346282
[TBL] [Abstract][Full Text] [Related]
6. Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared to dexamethasone: different effects on cytokines and apoptosis.
Sharabi A; Haviv A; Zinger H; Dayan M; Mozes E
Clin Immunol; 2006 May; 119(2):146-55. PubMed ID: 16503419
[TBL] [Abstract][Full Text] [Related]
7. B-cell activating factor (BAFF) plays a role in the mechanism of action of a tolerogenic peptide that ameliorates lupus.
Parameswaran R; Ben David H; Sharabi A; Zinger H; Mozes E
Clin Immunol; 2009 May; 131(2):223-32. PubMed ID: 19188092
[TBL] [Abstract][Full Text] [Related]
8. Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients.
Mauermann N; Sthoeger Z; Zinger H; Mozes E
Clin Exp Immunol; 2004 Sep; 137(3):513-20. PubMed ID: 15320900
[TBL] [Abstract][Full Text] [Related]
9. Induction of hippocampal neurogenesis by a tolerogenic peptide that ameliorates lupus manifestations.
Telerman A; Lapter S; Sharabi A; Zinger H; Mozes E
J Neuroimmunol; 2011 Mar; 232(1-2):151-7. PubMed ID: 21129786
[TBL] [Abstract][Full Text] [Related]
10. Protein interaction for an interferon-inducible systemic lupus associated gene, IFIT1.
Ye S; Pang H; Gu YY; Hua J; Chen XG; Bao CD; Wang Y; Zhang W; Qian J; Tsao BP; Hahn BH; Chen SL; Rao ZH; Shen N
Rheumatology (Oxford); 2003 Oct; 42(10):1155-63. PubMed ID: 12777642
[TBL] [Abstract][Full Text] [Related]
11. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.
Feng X; Wu H; Grossman JM; Hanvivadhanakul P; FitzGerald JD; Park GS; Dong X; Chen W; Kim MH; Weng HH; Furst DE; Gorn A; McMahon M; Taylor M; Brahn E; Hahn BH; Tsao BP
Arthritis Rheum; 2006 Sep; 54(9):2951-62. PubMed ID: 16947629
[TBL] [Abstract][Full Text] [Related]
12. Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus.
Nzeusseu Toukap A; Galant C; Theate I; Maudoux AL; Lories RJ; Houssiau FA; Lauwerys BR
Arthritis Rheum; 2007 May; 56(5):1579-88. PubMed ID: 17469140
[TBL] [Abstract][Full Text] [Related]
13. Indoleamine-2,3-dioxygenase in murine and human systemic lupus erythematosus: Down-regulation by the tolerogeneic peptide hCDR1.
Sthoeger Z; Sharabi A; Zinger H; Asher I; Mozes E
Clin Immunol; 2018 Dec; 197():34-39. PubMed ID: 30170030
[TBL] [Abstract][Full Text] [Related]
14. A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus.
Mozes E; Sharabi A
Autoimmun Rev; 2010 Nov; 10(1):22-6. PubMed ID: 20659591
[TBL] [Abstract][Full Text] [Related]
15. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation.
Luger D; Dayan M; Zinger H; Liu JP; Mozes E
J Clin Immunol; 2004 Nov; 24(6):579-90. PubMed ID: 15622442
[TBL] [Abstract][Full Text] [Related]
16. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus.
Kirou KA; Lee C; George S; Louca K; Papagiannis IG; Peterson MG; Ly N; Woodward RN; Fry KE; Lau AY; Prentice JG; Wohlgemuth JG; Crow MK
Arthritis Rheum; 2004 Dec; 50(12):3958-67. PubMed ID: 15593221
[TBL] [Abstract][Full Text] [Related]
17. Expression profile of HIN200 in leukocytes and renal biopsy of SLE patients by real-time RT-PCR.
Kimkong I; Avihingsanon Y; Hirankarn N
Lupus; 2009 Oct; 18(12):1066-72. PubMed ID: 19762380
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of TIPE2 mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus.
Li D; Song L; Fan Y; Li X; Li Y; Chen J; Zhu F; Guo C; Shi Y; Zhang L
Clin Immunol; 2009 Dec; 133(3):422-7. PubMed ID: 19748832
[TBL] [Abstract][Full Text] [Related]
19. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model.
Sharabi A; Luger D; Ben-David H; Dayan M; Zinger H; Mozes E
J Immunol; 2007 Oct; 179(8):4979-87. PubMed ID: 17911582
[TBL] [Abstract][Full Text] [Related]
20. Shared and unique gene expression in systemic lupus erythematosus depending on disease activity.
Sandrin-Garcia P; Junta CM; Fachin AL; Mello SS; Baião AM; Rassi DM; Ferreira MC; Trevisan GL; Sakamoto-Hojo ET; Louzada-Júnior P; Passos GA; Donadi EA
Ann N Y Acad Sci; 2009 Sep; 1173():493-500. PubMed ID: 19758191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
